Michael C. Wimer

Array ( [id] => 20671864 [patent_doc_number] => 12612364 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-28 [patent_title] => Salts and solid forms of 4-hydroxy- [patent_app_type] => utility [patent_app_number] => 19/408193 [patent_app_country] => US [patent_app_date] => 2025-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 32008 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19408193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20458251 [patent_doc_number] => 20260007671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => TREATMENT OF HCM WITH PYRIMIDINEDIONE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 19/288391 [patent_app_country] => US [patent_app_date] => 2025-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19288391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20335421 [patent_doc_number] => 20250339541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS [patent_app_type] => utility [patent_app_number] => 19/192108 [patent_app_country] => US [patent_app_date] => 2025-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84686 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 351 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19192108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20098847 [patent_doc_number] => 20250228783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-17 [patent_title] => PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 19/172172 [patent_app_country] => US [patent_app_date] => 2025-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19172172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20700281 [patent_doc_number] => 12622972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-12 [patent_title] => ASGPR-binding compounds for the degradation of extracellular proteins [patent_app_type] => utility [patent_app_number] => 19/081876 [patent_app_country] => US [patent_app_date] => 2025-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 139 [patent_no_of_words] => 84942 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 370 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19081876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20120411 [patent_doc_number] => 20250235442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-24 [patent_title] => Piperidine Urea Derivatives for Use as Inotropic Agents [patent_app_type] => utility [patent_app_number] => 19/060522 [patent_app_country] => US [patent_app_date] => 2025-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19060522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20057327 [patent_doc_number] => 20250195549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-19 [patent_title] => NEW USE [patent_app_type] => utility [patent_app_number] => 18/972566 [patent_app_country] => US [patent_app_date] => 2024-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18972566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19769847 [patent_doc_number] => 20250051273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => Glucose and Lipid Metabolism Regulating Agents, Pharmaceutical Compositions Comprising the Same, and Treatment Methods [patent_app_type] => utility [patent_app_number] => 18/755133 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19915222 [patent_doc_number] => 12290568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => ASGPR-binding compounds for the degradation of extracellular proteins [patent_app_type] => utility [patent_app_number] => 18/653610 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 162 [patent_no_of_words] => 85073 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 353 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447416 [patent_doc_number] => 20240307546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS [patent_app_type] => utility [patent_app_number] => 18/653655 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 391 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417225 [patent_doc_number] => 20240293348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury [patent_app_type] => utility [patent_app_number] => 18/646642 [patent_app_country] => US [patent_app_date] => 2024-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18646642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448846 [patent_doc_number] => 20240308976 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/640889 [patent_app_country] => US [patent_app_date] => 2024-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554836 [patent_doc_number] => 20240366628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => USE OF ZINC PORPHYRIN AS AN ANTIMICROBIAL [patent_app_type] => utility [patent_app_number] => 18/638849 [patent_app_country] => US [patent_app_date] => 2024-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510456 [patent_doc_number] => 20240342142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) [patent_app_type] => utility [patent_app_number] => 18/628366 [patent_app_country] => US [patent_app_date] => 2024-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343499 [patent_doc_number] => 20240252462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION [patent_app_type] => utility [patent_app_number] => 18/627708 [patent_app_country] => US [patent_app_date] => 2024-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18627708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402080 [patent_doc_number] => 20240285591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) [patent_app_type] => utility [patent_app_number] => 18/628353 [patent_app_country] => US [patent_app_date] => 2024-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19815006 [patent_doc_number] => 20250073213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST [patent_app_type] => utility [patent_app_number] => 18/621850 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19367349 [patent_doc_number] => 12059409 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-08-13 [patent_title] => Pharmaceutical composition for modified release [patent_app_type] => utility [patent_app_number] => 18/613270 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 9700 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613270 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19331355 [patent_doc_number] => 20240245785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS [patent_app_type] => utility [patent_app_number] => 18/584914 [patent_app_country] => US [patent_app_date] => 2024-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19584899 [patent_doc_number] => 20240382456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => SYNERGISTIC COMBINATION THERAPY FOR TREATING ALS [patent_app_type] => utility [patent_app_number] => 18/541375 [patent_app_country] => US [patent_app_date] => 2023-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541375 [rel_patent_id] =>[rel_patent_doc_number] =>)